We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mycoplasmas Frequently Cause Congenital Fetal Infection

By Labmedica staff writers
Posted on 15 Jan 2008
Premature babies should be screened for genital mycoplasma, which are a frequent cause of congenital infection. More...


Mycoplasmas are surface parasites of the human respiratory and urogenital tracts. They are spherical to filamentous cells with no cell walls. Twenty-three percent of neonates born between 23 and 32 weeks of gestation were found to have positive umbilical blood cultures for two genital mycoplasmas--Ureaplasma urealyticum and Mycoplasma hominis.

Although these two mycoplasmas are found in 80% of vaginal and cervical fluids, infants are not generally screened for these infections. The finding that about one-quarter of early preterm infants is already infected at birth is important for reducing adverse outcomes. These newborns had a higher incidence of neonatal systemic inflammatory response syndrome (SIRS), higher incidence of bronchopulmonary dysplasia (BPD), higher serum concentrations of interleukin (IL)-6, and more evidence of placental inflammation than those with negative cultures. It was found that the earlier the gestational age at delivery, the higher the rate of a positive umbilical cord blood culture.

The study was performed by the Alabama Preterm Birth Study (USA), and included 457 consecutive deliveries of infants born at 23-32 weeks' gestation from 1996 to 2001. It focused on a subset of 351 women/infant pairs in the population who had umbilical cord blood cultures for U. urealyticum and M. hominis.

Robert Goldenberg, M.D., professor, department of obstetrics and gynecology, Drexel University College of Medicine (Philadelphia, PA, USA) stated, "Given the frequency of these infections and their association with SIRS and [probably] with BPD, it seems reasonable to determine if infants in these categories would benefit from routine culture for U. urealyticum and/or M. hominis and subsequent treatment with an antibiotic effective against these organisms. Similarly, we question whether treatment of women likely to deliver an early gestational age infant with an antibiotic effective against these organisms might reduce subsequent neonatal morbidity and mortality.”

The study appeared in the January 2008 issue of the American Journal of Obstetrics & Gynecology. In an accompanying editorial, professors Roberto Romero, M.D., form the Center of Molecular Medicine, Wayne State University (Detroit, MI, USA) and Thomas J. Garite, from the University of California (Irvine, CA, USA) wrote, "The initial uncertainties of whether genital mycoplasmas can cause fetal/neonatal disease are disappearing in light of the accumulating evidence that these microorganisms have been implicated in neonatal sepsis, pneumonia, meningitis, and brain damage. Moreover, colonization of the neonatal respiratory tract with these organisms is a risk factor for chronic lung disease. The detection of genital mycoplasmas is not part of routine clinical practice in obstetrics and neonatology. Similarly, standard treatment for suspected neonatal sepsis does not include antibiotics effective against these microorganisms.”

Editor's note: certain species of U. urealyticum have now been classified as U. parvum, a new species.


Related Links:
Drexel University College of Medicine
Wayne State University
University of California, Irvine

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.